MedPath

Th17 Inducing Cytokines Pregnancy and After Postpartum

Completed
Conditions
Pregnancy
Interventions
Other: Saliva collection
Other: GCF collection
Registration Number
NCT03449186
Lead Sponsor
Aydin Adnan Menderes University
Brief Summary

The aim of this study was to investigate salivary and gingival crevicular fluid (GCF) levels of IL-17A, IL-17E, IL-6 AND IL-23 during 2/3 trimester of pregnancy and after delivery.

Detailed Description

IL-17 have a synergytic effect with IL-6 and IL-23. IL-17A levels elevated with periodontal diseases. Many systemical chronic conditions such as atherosclerosis and cardiovascular disease, pregnancy may contribute increasing of IL-17 family cytokine.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
114
Inclusion Criteria
  • women 2 and 3 trimester of their pregnancy
Exclusion Criteria
  • any known systemic disease,
  • periodontal treatment within the last six months,
  • patients having less than 10 teeth,
  • smokers,
  • individuals with a BMI > 30 kg/m2,
  • gestational diabetes and preeclampsia during pregnancy.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Postpartum groupSaliva collectionPostpartum women 6 months after giving birth recalled. Saliva and GCF samples were collected and clinical periodontal measurements were made.
Postpartum groupGCF collectionPostpartum women 6 months after giving birth recalled. Saliva and GCF samples were collected and clinical periodontal measurements were made.
Pregnancy groupSaliva collectionWomen, who were in their second trimester (weeks 16-24) or third trimester (weeks 25-34)selected for the study. Saliva and GCF samples were collected and clinical periodontal measurements were made gently
Pregnancy groupGCF collectionWomen, who were in their second trimester (weeks 16-24) or third trimester (weeks 25-34)selected for the study. Saliva and GCF samples were collected and clinical periodontal measurements were made gently
Primary Outcome Measures
NameTimeMethod
Changing Il-17A levels6 month

Salivary and GCF level measured by ELISA

Secondary Outcome Measures
NameTimeMethod
Changing IL-6 levels6 month

Salivary and GCF level measured by ELISA

Changing IL-23 levels6 month

Salivary and GCF level measured by ELISA

Changing IL-17E levels6 month

Salivary and GCF level measured by ELISA

© Copyright 2025. All Rights Reserved by MedPath